Sunday, March 16, 2025 | 01:14 PM ISTहिंदी में पढें
Business Standard
Notification Icon
userprofile IconSearch

SII, Bharat Biotech to get bulk of Rs 15K-crore profit pool: Report

At present, SII sells its vaccine Covishield to the Centre for Rs 150 per dose, to state governments for Rs 300 and to private hospitals for Rs 600.

Coronavirus vaccine, covid-19, vaccination
Premium

When the vaccine is available at the retail level, the prices and, in turn, the margins are likely to be higher.

Sohini DasSurajeet Das Gupta Mumbai/New Delhi
With India expected to spend Rs 75,000 crore (Centre, states and private sector) in calendar year 2021 on vaccines, including Rs 3,200 crore spent till April-end to combat Covid, Serum Institute of India (SII) and Bharat Biotech would be the key beneficiaries. According to an analyst report by Investec, Serum Institute and Bharat Biotech will control over 67 per cent (Serum Institute 43 per cent and Bharat Biotech 24 per cent) of the value market share and 73 per cent in terms of volumes. Sputnik V, the Russian Covid vaccine, will be the third player with a 14 per cent

What you get on BS Premium?

  • Unlock 30+ premium stories daily hand-picked by our editors, across devices on browser and app.
  • Pick your 5 favourite companies, get a daily email with all news updates on them.
  • Full access to our intuitive epaper - clip, save, share articles from any device; newspaper archives from 2006.
  • Preferential invites to Business Standard events.
  • Curated newsletters on markets, personal finance, policy & politics, start-ups, technology, and more.
VIEW ALL FAQs

Need More Information - write to us at assist@bsmail.in